Wave Life Sciences

Advertisement

cGxPJobs Banner

Wave Life Sciences Initiates Phase 2a INLIGHT™ Trial of WVE-007 for Obesity and Cardiometabolic Diseases

CAMBRIDGE, Mass., June 24, 2026 Wave Life Sciences announced the initiation of the Phase 2a multidose portion of the...

By cGxPwire Editor
June 26, 2026

Read More

Wave Life Sciences Advances RNA Innovation Ahead of Q3 2025 Results

CAMBRIDGE, Mass., November 4, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company pioneering the use...

By cGxPwire Editor
November 5, 2025

Read More

Wave Life Sciences’ RNA Breakthrough Targets Obesity and Liver Disorders

BOSTON, October 29, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology leader in RNA medicines, has...

By cGxPwire Editor
October 30, 2025

Read More

Advertisement

cGxPJobs

Directory